Search results for "BIP"

showing 10 items of 1908 documents

Identification of two novel polymorphisms and a rare deletion variant in the human dopamine D4 receptor gene

1995

We report two novel polymorphisms and a rare deletion variant in the human dopaine D4 receptor gene. The two polymorphisms are characterized by single base pair substitutions, namely a G-->C transversion changing codon 11 from GGG (encoding Gly) to CGG (encoding Arg) and a C-->T transition in position -11 upstream from the start codon. The Arg11 variant occurs at a frequency of about 1% and the C-->T transition at a frequency of about 7% in German control subjects (n = 148). Allele frequencies observed in patients suffering from schizophrenia (n = 256) and bipolar affective disorder (n = 99) were similar. The deletion variant is characterized by a 21 bp deletion affecting codons 36 to 42 co…

AdultObsessive-Compulsive DisorderBipolar DisorderMolecular Sequence DataBiologymedicine.disease_causePolymerase Chain ReactionGene FrequencyStart codonReference ValuesLeukocytesGeneticsmedicineHumansPoint MutationAmino Acid SequenceAge of OnsetCodonTransversionGeneAllele frequencyBiological PsychiatryGenetics (clinical)DNA PrimersRepetitive Sequences Nucleic AcidSequence DeletionGeneticsMutationBase SequenceTransition (genetics)Receptors Dopamine D2Receptors Dopamine D4Genetic VariationDNAExonsMiddle Agedmedicine.diseasePsychiatry and Mental healthTransmembrane domainSchizophreniaSchizophreniaPanic DisorderPolymorphism Restriction Fragment Length
researchProduct

Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind…

2019

Background: Basal cell carcinomas (BCCs) exhibit aberrant activation of the hedgehog pathway. Sonidegib is a hedgehog pathway inhibitor approved for the treatment of locally advanced BCC (laBCC) and metastatic BCC (mBCC) based on primary results of the BOLT study [Basal Cell Carcinoma Outcomes with LDE225 (sonidegib) Treatment]. Objectives: This is the final 42-month analysis of the BOLT study, evaluating the efficacy and safety of sonidegib. Methods: Adults with no prior hedgehog pathway inhibitor therapy were randomized in a 1 : 2 ratio to sonidegib 200 mg or 800 mg once daily. Treatment continued for up to 42 months or until disease progression, unacceptable toxicity, death, study termin…

AdultOncologymedicine.medical_specialtySkin NeoplasmsPyridinesmedicine.medical_treatmentAntineoplastic AgentsDermatologySonidegiblaw.invention030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled triallawInternal medicinemedicineCarcinomaHumansHedgehog ProteinsBasal cell carcinomaAdverse effectbusiness.industryBiphenyl Compoundsmedicine.diseaseRadiation therapyClinical trialBiphenyl compoundchemistryCarcinoma Basal CellbusinessBritish Journal of Dermatology
researchProduct

Use of long acting injectable aripiprazole before and through pregnancy in bipolar disorder: a case report

2019

Abstract Background Long-acting injectable (LAI) antipsychotics for psychotic disorders provide advantages in treatment compliance, but data on their use in pregnancy are very limited. We present a clinical case of aripiprazole LAI use in pregnancy. Case presentation A 43-year-old woman diagnosed with bipolar disorder, with several relapses due to treatment interruption while trying to conceive. Finally, aripiprazole LAI treatment was planned by mutual agreement between doctor and the patient, who took aripiprazole LAI before and during pregnancy. She gave birth at 40 weeks to a 3500 g baby girl with no congenital malformations, who was healthy at 5 months after delivery. Conclusion As far …

AdultPediatricsmedicine.medical_specialtyTime FactorsBipolar disordermedicine.medical_treatmentvirusesAripiprazoleCase Report030226 pharmacology & pharmacyInjections IntramuscularAntipsychotic03 medical and health sciences0302 clinical medicineimmune system diseasesPregnancylcsh:RA1190-1270medicineHumansPharmacology (medical)Bipolar disorderAntipsychoticlcsh:Toxicology. PoisonsPharmacologyDosage FormsPregnancybusiness.industrylcsh:RM1-950Pregnancy Outcomevirus diseasesCongenital malformationsmedicine.diseasePregnancy ComplicationsLong actinglcsh:Therapeutics. PharmacologyTreatment interruptionLong-acting injectable aripiprazoleAripiprazoleFemaleClinical casebusinessmedicine.drugAntipsychotic AgentsFollow-Up StudiesBMC Pharmacology and Toxicology
researchProduct

Dietary exposure and risk assessment of polychlorinated dibenzo-p-dioxins, polychlorinated dibenzofurans and dioxin-like polychlorinated biphenyls of…

2018

Dietary exposure of the Valencia Region population to polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and PCBs was assessed in the Region of Valencia in 2010–2011. A total of 7700 food samples were collected. Occurrence data were combined with consumption data to estimate dietary exposure in adults (>15 years of age) and young people (6–15 years of age). The estimated intake was calculated by a probabilistic approach. Average intake levels (upper-bound scenario) were 1.58 and 2.76 pg toxic equivalent (TEQ) kg−1 body weight (bw) day−1 for adults and young people, respectively. These average intakes are within range of the tolerable daily intake of 1–4 pg W…

AdultTolerable daily intakePolychlorinated DibenzodioxinsAdolescentHealth Toxicology and MutagenesisPopulationPolychlorinated dibenzodioxinsFood Contamination010501 environmental sciencesToxicologyRisk Assessment01 natural sciencesDietary ExposureYoung Adultchemistry.chemical_compoundAnimal scienceHumansMedicineChildeducationAged0105 earth and related environmental sciencesAged 80 and overeducation.field_of_studybusiness.industryDietary exposure010401 analytical chemistryPublic Health Environmental and Occupational HealthGeneral ChemistryGeneral MedicineDibenzofurans PolychlorinatedMiddle AgedPolychlorinated BiphenylsFood Analysis0104 chemical scienceschemistrySpainEnvironmental PollutantsbusinessRisk assessmentFood AnalysisPolychlorinated dibenzofuransFood ScienceFood contaminant
researchProduct

Cold loops applied to bipolar resectoscope: A safe "one-step" myomectomy for treatment of submucosal myomas with intramural development

2015

AIM: To assess the safety and efficacy of cold loop myomectomy applied to bipolar resectoscope to perform "one-step" myomectomy of submucosal myomas with intramural involvement. METHODS: Seventy-two patients with at least one symptomatic G1 or G2 myoma (Wamsteker's classification) underwent cold loop myomectomy from January 2011 to January 2013. All surgical procedures were performed using a 26Fr resectoscope and bipolar energy source. At one month after the procedure, all patients underwent an office hysteroscopy check-up. A subgroup of seven infertile patients underwent an office hysteroscopy every two-weeks to evaluate recovery time of the myometrial fovea. RESULTS: Resectoscopic myomect…

Adulthysteroscopybipolar resectoscope; cold loop; hysteroscopic myomectomy; hysteroscopy; submucosal myomasLeiomyomaMiddle Agedbipolar resectoscopeSettore MED/40 - Ginecologia E Ostetriciasubmucosal myomasUterine MyomectomyUterine NeoplasmsHumansFemaleProspective Studieshysteroscopic myomectomycold loop
researchProduct

Prenatal exposure to mercury and longitudinally assessed fetal growth: Relation and effect modifiers.

2016

Background: Prenatal mercury exposure has been related to reductions in anthropometry at birth. Levels of mercury have been reported as being relatively elevated in the Spanish population. Objective: To investigate the relation between prenatal exposure to mercury and fetal growth. Methods: Study subjects were pregnant women and their newborns (n:1867) participating in a population-based birth cohort study set up in four Spanish regions from the INMA Project. Biparietal diameter (BPD), femur length (FL), abdominal circumference (AC), and estimated fetal weight (EFW) were measured by ultrasounds at 12, 20, and 34 weeks of gestation. Size at and growth between these points were assessed by st…

Adultmedicine.medical_specialtyAdolescentPopulationchemistry.chemical_elementFetal growth010501 environmental sciencesPolychlorinated biphenyl 15301 natural sciencesBiochemistryFetal Development03 medical and health sciencesYoung Adult0302 clinical medicinePregnancySeafood consumptionMedicineHumans030212 general & internal medicineLongitudinal Studieseducation0105 earth and related environmental sciencesGeneral Environmental SciencePregnancyeducation.field_of_studybusiness.industryObstetricsMercuryAnthropometrymedicine.diseaseConfidence intervalMercury (element)chemistryMaternal ExposureCord bloodGestationFemaleGeometric meanbusinessEnvironmental research
researchProduct

The effects of high heeled shoes on female gait: a review.

2013

Walking is the most common form of human locomotion. From a motor control perspective, human bipedalism makes the task of walking extremely complex. For parts of the step cycle, there is only one foot on the ground, so both balance and propulsion are required in order for the movement to proceed smoothly. One condition known to compound the difficulty of walking is the use of high heeled shoes, which alter the natural position of the foot–ankle complex, and thereby produce a chain reaction of (mostly negative) effects that travels up the lower limb at least as far as the spine. This review summarises recent studies that have examined acute and chronic effects of high heels on balance and lo…

Adultmedicine.medical_specialtyBiophysicsNeuroscience (miscellaneous)Poison controlElectromyographyWalkingYoung AdultPhysical medicine and rehabilitationGait (human)medicineHumansBipedalismHuman locomotionGaitBalance (ability)BackHipmedicine.diagnostic_testElectromyographyFootPerspective (graphical)Motor controlSpineBiomechanical PhenomenaShoesPhysical therapyFemaleHeelNeurology (clinical)AnklePsychologyLocomotionJournal of electromyography and kinesiology : official journal of the International Society of Electrophysiological Kinesiology
researchProduct

Alterations in the expression of PSA-NCAM and synaptic proteins in the dorsolateral prefrontal cortex of psychiatric disorder patients.

2012

Alterations in the structure and physiology of the prefrontal cortex (PFC) have been found in different psychiatric disorders and some of them involve inhibitory networks, especially in schizophrenia and major depression. Changes in the structure of these networks may be mediated by the polysialylated neural cell adhesion molecule (PSA-NCAM), a molecule related to neuronal structural plasticity, expressed in the PFC exclusively by interneurons. Different studies have found that PSA-NCAM expression in the hippocampus and the amygdala is altered in schizophrenia, major depression and animal models of these disorders, in parallel to changes in the expression of molecules related to inhibitory …

Adultmedicine.medical_specialtyBipolar DisorderSynaptophysinHippocampusPrefrontal CortexNeural Cell Adhesion Molecule L1NeurotransmissionHippocampusmedicineNeuropilHumansPsychiatryPrefrontal cortexAgedDepressive Disorder MajorNeuronal PlasticitybiologyGlutamate DecarboxylaseGeneral NeuroscienceMental DisordersNeural InhibitionMiddle AgedAmygdalaDorsolateral prefrontal cortexmedicine.anatomical_structurenervous systemSynaptic plasticitySynapsesVesicular Glutamate Transport Protein 1Synaptophysinbiology.proteinSchizophreniaSialic AcidsNeural cell adhesion moleculePsychologyNeuroscienceNeuroscience letters
researchProduct

Organochlorine Compounds and Ultrasound Measurements of Fetal Growth in the INMA Cohort (Spain)

2014

This study was funded by grants from the EU (European Union): NEWGENERIS FP6-2003- Food-3-A-016320, FP7-ENV-2011 cod 282957, HEALTH.2010.2.4.5-1; and by grants from Spain: Instituto de Salud Carlos III (Red INMA G03/176, CB06/02/0031, and FIS-FEDER PI03/1615, PI04/1509, PI04/1112, PI04/1931, PI04/2018, PI04/1436, PI05/1079, PI05/1052, PI06/1213, PI07/0314, PI08/1151, PI09/02647, PI09/02311, PI11/01007, PI11/02591, PI11/02038, PI13/1944, PI13/02429, PI14/0891, PI14/1687, and Miguel Servet CP11/00178 and CP13/00054), Conselleria de Sanitat Generalitat Valenciana, Generalitat de Catalunya (CIRIT 1999SGR 00241), Diputación Foral de Guipúzcoa (DFG/004), Departamento de Sanidad y Consumo Gobierno…

Adultmedicine.medical_specialtyHealth Toxicology and MutagenesisPhysiologyUltrasonography PrenatalFetal Developmentchemistry.chemical_compoundPregnancyInternal medicinemedicineHydrocarbons ChlorinatedHumansFetusPregnancybusiness.industryUltrasoundPublic Health Environmental and Occupational HealthPolychlorinated biphenylHexachlorobenzeneAnthropometrymedicine.disease3. Good healthEndocrinologychemistryMaternal ExposureSpainCohortChildren's HealthGestationFemalebusiness
researchProduct

A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder

2012

Abstract Background β-Adrenoceptor agonists are effective in animal models of bladder dysfunction, and the human bladder primarily expresses the β3 receptor subtype. Objective To evaluate the efficacy and tolerability of the highly selective and potent β3-adrenoceptor agonist solabegron in a clinical proof-of-concept study in incontinent women with overactive bladder (OAB). Design, setting, and participants This was a randomized, double-blind trial in adult women with OAB (one or more 24-h incontinence episodes and eight or more average 24-h micturitions). Interventions Solabegron 50mg ( n =88), solabegron 125mg ( n =85), or placebo ( n =85)—all twice daily—were administered. Outcome measur…

Adultmedicine.medical_specialtyTime FactorsUrologymedia_common.quotation_subjectUrinary BladderArgentinaTaiwanPlacebo-controlled studyUrologyUrinationAdrenergic beta-3 Receptor AgonistsPlaceboBenzoatesUrinationDrug Administration ScheduleSouth AfricaYoung AdultSolabegronDouble-Blind MethodRepublic of KoreamedicineHumansAgedmedia_commonAniline CompoundsUrinary Bladder Overactivebusiness.industryBiphenyl CompoundsAustraliaMiddle Agedmedicine.diseaseEuropeUrodynamicsTreatment OutcomeUrinary IncontinenceBlood pressureOveractive bladderTolerabilityAmbulatoryLinear ModelsFemalebusinessNew Zealandmedicine.drugEuropean urology
researchProduct